BioAegis announced publication: ‘Delayed administration of recombinant plasma gelsolin improves survival in a murine model of severe influenza’

, ,

On Dec. 12, 2019, BioAegis Therapeutics announced publication of new research findings with recombinant human plasma gelsolin in influenza. The research demonstrated that recombinant human plasma gelsolin therapy dramatically improves survival in a highly lethal influenza animal model.

Tags:

,

Source: BioAegis Therapeutics
Credit:

Visit News/History Source
Transfection Has Never Been So Easy With Avalanche® Transfection Reagents for Cancer Cells, Primary Cells, And Other Difficult-To-Transfect Cells.Primary Cells, And Other Difficult-To-Transfect Cells.